AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/9/2026

1. USO
2. SPY
3. META
4. COST
5. MSFT
6. MU
7. RMR
8. RXT
9. AAPL
10. CME

Go back to AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
(NASDAQ: ACIU) Delayed: 2.58 +0.06 (2.38%)
Previous Close $2.52    52 Week High $19.97 
Open $2.51    52 Week Low $10.36 
Day High $2.62    P/E N/A 
Day Low $2.50    EPS $0.00 
Volume 37,363